Immunogenicity assessment of intravenous administration of reslizumab in patients with asthma in phase 3 clinical studies

L. Zou (West Chester, United States of America), L. Pukac (West Chester, United States of America), Y. Shalit (Petah Tikva, Israel), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America), P. Liu (West Chester, United States of America)

Source: International Congress 2018 – New developments in the treatment of asthma
Session: New developments in the treatment of asthma
Session type: Thematic Poster
Number: 1032
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Zou (West Chester, United States of America), L. Pukac (West Chester, United States of America), Y. Shalit (Petah Tikva, Israel), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America), P. Liu (West Chester, United States of America). Immunogenicity assessment of intravenous administration of reslizumab in patients with asthma in phase 3 clinical studies. 1032

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: